• EzBiome, a wholly owned U.S. subsidiary of CJ Bioscience, will raise USD 5.57 million through a rights issue subscribed entirely by its parent.
• The subsidiary will issue 185,667 common shares at USD 30 each, with payment due Nov. 23, 2026.
• Proceeds will repay existing borrowings to prepare for liquidation, with KRW 7.25 billion earmarked for debt repayment.
• Another KRW 299.62 million will fund operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CJ Bioscience Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261110900695), on November 10, 2026, and is solely responsible for the information contained therein.